💞 #Gate Square Qixi Celebration# 💞
Couples showcase love / Singles celebrate self-love — gifts for everyone this Qixi!
📅 Event Period
August 26 — August 31, 2025
✨ How to Participate
Romantic Teams 💑
Form a “Heartbeat Squad” with one friend and submit the registration form 👉 https://www.gate.com/questionnaire/7012
Post original content on Gate Square (images, videos, hand-drawn art, digital creations, or copywriting) featuring Qixi romance + Gate elements. Include the hashtag #GateSquareQixiCelebration#
The top 5 squads with the highest total posts will win a Valentine's Day Gift Box + $1
Rongchang Bio responds to Pfizer's $200 million impairment of Vidisutuximab: Pfizer's conclusion is based on market competition environment.
On February 7th, Jinshi Data reported that Rongchang Biology responded to the reporter's inquiry about the devaluation of its vedolizumab (RC48) by its partner Pfizer, which amounted to a reduction of 200 million US dollars. Rongchang Biology stated that this devaluation is due to changes in the market competitive environment compared to the time of the transaction, and some indications for vedolizumab have not progressed as expected, resulting in a decrease in expected value compared to the transaction time. This conclusion was made by Pfizer based on its judgment of the market competitive environment. Previously, in August 2021, Rongchang Biology authorized the overseas rights of its HER2ADC (antibody-drug conjugate) vedolizumab to ADCleading company Seagen. In 2023, Seagen was acquired by Pfizer. Currently, Pfizer is advancing the indication of vedolizumab for urothelial carcinoma overseas.